Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Complicaciones vasculares después del trasplante renal (DAN-PTRAIII)

12 de octubre de 2026 actualizado por: University of Aarhus

Complicaciones vasculares después del trasplante renal: un estudio prospectivo multicéntrico nacional - El estudio DAN-PTRAIII

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.

Descripción general del estudio

Descripción detallada

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

Tipo de estudio

De observación

Inscripción (Estimado)

60

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Mark Reinhard, MD, PhD
  • Número de teléfono: +45 40460321
  • Correo electrónico: markrein@rm.dk

Copia de seguridad de contactos de estudio

  • Nombre: Henrik Birn, MD, DMSc
  • Correo electrónico: hb@clin.au.dk

Ubicaciones de estudio

      • Aarhus, Dinamarca, 8200
        • Reclutamiento
        • Aarhus University Hospital
        • Contacto:
      • Copenhagen, Dinamarca, 2100
      • Odense, Dinamarca, 5000
        • Reclutamiento
        • Odense University Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

Descripción

Inclusion Criteria:

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.

  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.

  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Concurrent biopsy demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Kidney Transplant Recipients

Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

Catheter-based angiography performed in accordance with the study protocol.

Measurement of translesional pressure gradients performed in accordance with the study protocol.

Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in measured glomerular filtration rate (mGFR).
Periodo de tiempo: Baseline and 3 months post-PTA.

Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

Baseline and 3 months post-PTA.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in estimated glomerular filtration rate (eGFR).
Periodo de tiempo: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
Periodo de tiempo: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Periodo de tiempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
Periodo de tiempo: Baseline and 3 months post-PTA.

Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline.

Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Baseline and 3 months post-PTA.
Number of clinical events after PTA.
Periodo de tiempo: 10 years post-PTA.

Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:

  1. Cardiovascular death
  2. Renal death
  3. Death from non-cardiovascular and non-renal causes
  4. Undetermined cause of death
  5. Stroke
  6. Myocardial infarction
  7. Hospitalization for heart failure
  8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease
  9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days
  10. Biopsy-proven rejection
  11. Need for repeat PTA due to restenosis or in-stent thrombosis
  12. Other relevant clinical events
10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
Periodo de tiempo: 30 days post-PTA.

All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):

  1. Vessel rupture
  2. Vessel dissection
  3. Vessel occlusion
  4. Vessel perforation
  5. Stent thrombosis
  6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route)
  7. Pulmonary oedema
  8. Major bleeding requiring transfusion
  9. Embolisation due to bleeding or another adverse event
  10. Nephrectomy due to bleeding or another adverse event
  11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention
  12. Requirement for acute dialysis
  13. Clinical events, including all-cause mortality, as defined above
  14. Other relevant adverse events (AEs)
30 days post-PTA.
Doppler ultrasound.
Periodo de tiempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
Periodo de tiempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Intravascular ultrasound.
Periodo de tiempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Periodo de tiempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
Periodo de tiempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de mayo de 2026

Finalización primaria (Estimado)

31 de marzo de 2031

Finalización del estudio (Estimado)

1 de junio de 2031

Fechas de registro del estudio

Enviado por primera vez

1 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de abril de 2026

Publicado por primera vez (Actual)

15 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de octubre de 2026

Última verificación

1 de mayo de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir